Findit, Inc.
FDIT
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.13M
Close$
$-0.00
102.9% downside
Current Fair Value
102.9% downsideOvervalued by 102.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $30.13 Million |
|---|---|
| Enterprise Value | $32.31 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | -2.77 |
| Outstanding Shares | 969,173,181 |
Return
| Return on Equity | 28.74% |
|---|---|
| Return on Assets | -386.56% |
| Return on Invested Capital | 11.33% |
Valuation & Multiples
| P/E Ratio | -3.46 |
|---|---|
| PEG | 3.84 |
| Price to Sales | - |
| Price to Book Ratio | -0.03 |
| Enterprise Value to Revenue | 18.3 |
| Enterprise Value to EBIT | -78.13 |
| Enterprise Value to Net Income | -25 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | -0.49 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioRegenx, Inc.
6 employees
CEO: William Resides BioRegenx, Inc. develops, manufactures, and sells medical test equipment, science-based nutritional products, and AI-driven health monitoring technologies. Its products include the GlycoCheck system for microvascular health assessment, t...